跳至主要内容
临床试验/ACTRN12608000223336
ACTRN12608000223336已完成未知

The effect of anterior chamber protein concentration, gene polymorphisms and complement factors on visual acuity, contrast sensitivity, microperimetry, optical coherence tomography (OCT) findings and need of repeated drug injections in patients with exudative age related macular degeneration treated with intravitreal bevacizumab (Avastin) injection therapy.

Ilkka Immonen0 个研究点目标入组 60 人开始时间: 2008年4月28日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
60

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Non-randomised trial
主要目的
Treatment
盲法
Open (masking not used)

入排标准

年龄范围
50 Years 至 o limit(—)
性别
All

入选标准

  • •Patients with classic, predominantly classic, minimally classic or occult type of exudative AMD and visual acuity at least 20/200.

排除标准

  • •Prior treatment of exudative macular degeneration, prior intraocular surgery other than uncomplicated cataract surgery, uncomplicated cataract surgery within one year, diabetes, intraocular tumors, other retinal diseases or retinal vascular occlusions, prior retinal panphotocoagulation, prior significant intraocular inflammation or infection and poor co-operation.

研究者

发起方
Ilkka Immonen

相似试验